BN 52021 decreases alveolar macrophage-mediated lung injury in experimental extrinsic allergic alveolitis. by Tremblay, G
Letters  to  the  Editor
BN  52021  decreases  alveolar
macrophage-mediated  lung  injury  in
experimental  extrinsic  allergic  alveolitis
G.  Tremblay
Hˆ opital Laval,
2725 chemin Sainte-Foy, Qu´ ebec, Canada
EDITOR – We read with great interest the publication
from P´ erez-Arellano and colleagues.1 The aim of this
study  was  to  evaluate  the  participation  of  PAF  in
extrinsic allergic alveolitis. We would like to bring to
your  attention  the  fact  that  we  published  a  similar
study  a  few  years  ago.2 Both  studies  show  striking
methodological  similarities,  namely  the  use  of  the
same  antigen  to  induce  EAA  and  the  same  PAF
antagonist. However, we reported a decreased total
BAL  cell  counts  in  BN  52021  treated  animals  in
contrast to the results as described by P´ erez-Arellano
et  al.  We  acknowledge  that  they  looked  at  more
parameters than we did, but it would have been fair
just  to  mention  our  previous  publication  in  the
introduction and discuss discrepancies between their
and  our  results.  Considering  the  easy  access  to
published materials with databases such as PubMed,
we  question  if  such  an  omission  was  intentional,
especially  when  both  studies  reach  a  similar
conclusion.
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Reply  to  G.  Tremblay
J.L.  Perez-Arellano
Department of Medical Science and Surgery,
University of Las Palmas de Gran Canaria, Spain
EDITOR – We regret that Dr Tremblay’s work was not
mentioned in our paper. A more thorough searching
of the database might have found his paper, but at the
time we were unaware of its existence. For this we
would  ask  you  to  send  our  apologies  to  Dr
Tremblay.
However ,  we  disagree  with  a  number of  points
made by Dr Tremblay, namely:
(a) We do not think that there are ‘striking methodo-
logical similarities’ between both papers. Briefly,
we used an experimental model previously descri-
bed  in  hamsters  (Mediators  Inflamm  1995;  4:
43–48),  because  in  a  previous  review  (J  Invest
Allergol  Clin  Immunol 1992;  2: 219–228)  we
found  that  “the  model  has  proved  useful  for
studying  the  disease  since  it  reproduces  all  the
main features of it, namely, alveolitis, granuloma
formation,  the  production  of  precipitins  and  a
delayed hypersensitivity response”. However, Dr
Tremblay  and  coworkers  used  an  experimental
model developed in mice which has both advan-
tages  and  limitations  (e.g.  bronchoalveolar  T
helper response compared with the elevation in
suppressor/cytotoxic  lymphocytes  in  humans).
Furthermore,  they  used  an  intranasal  route  for
administration of antigen whereas in our work we
used  intratracheal  administration.  Moreover,  the
protocol of administration of the antigen and BN
52021  is  very  different  in  both  papers. These
differences  could  probably  explain  the  discrep-
ancies observed in the results obtained for total
and differential counts.
(b) Concerning  the  criticism  about  the  use  of  the
‘same antigen’, we should point out that Faenia
rectivirgula has  been  used  for  a  long  time  in
experimental models of extrinsic allergic alveoli-
tis  by  many  groups.1–3 Specifically,  we  use  the
protocol of Schuyler and Crooks4 as indicated in
our paper. Indeed, as mentioned in our paper (ref.
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Mediators of Inflammation, 8, 181–182 (1999)17), one of us (Prof. J.M. Lopez Novoa) has used
BN  52021  (provided  by  Dr  P.  Braquet)  prior to
1993  (the  date  of  publication  of  Dr Tremblay’s
paper). We  are therefore  very surprised that  Dr
Tremblay sees fit to draw attention to our use of
this antigen when it is so widely used by others,
and  strongly  refute  the  implication  in  his  final
sentence that we intentionally omitted to cite his
work.
(c) The methods used for the evaluation of the role of
PAF in the pathogenesis of EAA is very different in
both  papers.  Their  results  include  two  main
aspects: the number and type of cells recovered in
BAL,  and  the  production  of  eicosanoids  by
alveolar macrophages. In our work we evaluated
several  parameters  of  parenchymal  lung  disease
(not only alveolitis) and we measured PAF directly.
So, with the exception of BAL lavage (a technique
used in all papers that investigate the pathogene-
sis of interstitial lung disease) the rationale of the
work is totally different.
In conclusion, while we recognize the omission of
their  very  interesting  paper  from  our  paper,  we
strongly deny that this was in any way deliberate.
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